Glucomeo™ - Insulin and Nutrition Management
Forget about the conventional / intensive glucose control debate in the ICU! Why bother?
What really matters is to anticipate patient-specific response variability in real-time.
Ready? Set you preferred glycemic target band and treat patients with confidence any time...
No need for a complex, one-size-fits-all, tabled-based protocol anymore.
Glucomeo™ captures patient-specific response to treatment and forecasts blood glucose evolution over the next hours.
ICU teams have real-time insights and can adjust treatment easily. Whether it is for adjusting insulin or start/adjust/stop carbs inputs, you always know the risks.
We provide automation - removing human factor errors.
Thanks to our technology, patient-specific response to insulin and nutrition is analysed in real-time, and AI-based predictions are used to assess hypo- and hyper- glycemic risks.
We can thus give you the best option according to our patented clinically validated algorithm - but you are free to choose whether to see/use/change our optimal recommendations.
It is nothing else than a tool to make decision in a stress-free manner, with reminders and alarm system allowing to focus on other important care tasks.
This decision support software revolutionizes insulin and nutrition therapy, and helps in everyday management, improving control and patient outcomes, facilitating nurse workflow, and significantly reducing related costs of care.
"We ain't have any problem with glucose control in our ICU".
Are you really sure about that? Do you even actually know how well you are performing in your unit?
You'd be surprise to see how sub-optimal, variable, and risky patients are treated...
Want to know more about it ? Main clinical results are presented below, but please flick us an email to get in touch and have a live demo.
You can also send us patient data so we can run virtual trials and see how well you would have control your patients using Glucomeo™!
Main clinical results using Glucomeo™ technology
In published studies* including over 267 patients adult ICU patients, our unique patented technology was shown to achieve:
- 80% time in target band (80-145 mg/dL or 4.4-8.0 mmol/L)
- 0.004% severe hypoglycemia (40mg/dL or 2.2mmol/L)
- 85% goal feed reached by day 3
- 36% reduced time on protocol
High time in normolgycemic ranges, low incidence of hypoglycemia, and high nutrition intake are all associated with improved outcomes in the ICU.
And this is achieved with (typical) optimised workload ranging from 8 to 12 measurements per day depending on patient complexity.
Stewart K. et al., Safety, efficacy and clinical generalization of the STAR protocol: a retrospective analysis, 2016.
Stewart K. et al., Nutrition delivery of a model-based ICU glycaemic control system, 2018.
Uyttendaele V. et al., Clinical trial validation of the STAR-3D glycemic control framework, 2023.
Who is using Glucomeo™?
Glucomeo™ has treated over 2500 adult ICU patients to date in 4 hopitals across the world:
- Christchurch, New Zealand (where it is now the standard of care)
- Liège, Belgium (where it will soon be the standard of care)
- Gyula, Hungary
- Kuantan, Malaysia
We are also currently undertaking clinical trials in Neonatal Intensive Care Units (NICU).
Want to use Glucomeo™ and be in the list? Happy to take part in our clinical trials? Flick us an email!
Discover our in-silico trials toolbox
Based on years of research experience, insilicare developped a unique in-silico trials toolbox.
In-silico trials enable to simulate different treatments or protocols on virtual patients, characterised by their unique digital twin.
Such virtual simulations enable to assess the impact of a new protocol on patients prior further animal or clinical testing or use.
With our fully anonymised, high quality cohort data consisting of over 750 digital twins of real patients, you can simulate your new protocol and get a complete safety and performance report thanks to our expertise and excellence in medical statistics.